Premium
Therapeutic value of transcatheter arterial chemoembolization combined with portal vein embolization for primary hepatocellular carcinoma with portal vein tumor thrombus: A pilot study
Author(s) -
Tan Xuefen,
Xie Peng,
Liu Jibing,
Wu Huiyong,
Xie Yinfa
Publication year - 2015
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12272
Subject(s) - medicine , hepatocellular carcinoma , transcatheter arterial chemoembolization , oxaliplatin , cirrhosis , embolization , radiology , thrombus , portal vein , therapeutic effect , mitomycin c , gastroenterology , carcinoma , surgery , cancer , colorectal cancer
Aim To compare clinical outcome and safety of transcatheter arterial chemoembolization ( TACE ) + portal vein embolization ( PVE ) with TACE alone in hepatocellular c arcinoma ( HCC ) patients with portal vein tumor thrombus ( PVTT ). Methods We retrospectively collected patients of HCC with PVTT treated with TACE (5‐ FU , oxaliplatin and mitomycin) or TACE + PVE (doxorubicin) between O ctober 2000 and J uly 2008. Outcomes evaluated include overall survival, response to treatment and side effects. Results One hundred and sixteen patients were assessed. The median follow‐up of TACE group and TACE + PVE group was 83 and 85 months, respectively. The tumor response rates were respectively 48/64 and 49/52. The 1‐, 3‐ and 5‐year overall survival rates for the TACE and TACE + PVE groups were 39/64, 16/64, 0/64 and 42/52, 19/52, 6/52 respectively ( P = 0.015, 0.046 and 0.002, respectively). Three factors were shown as the risk factors which affect the survival of patients: treated by TACE + PVE or TACE ; type of PVTT ; and absence of cirrhosis. Conclusion TACE + PVE may be better than TACE alone to treat primary HCC with PVTT .